Clinical trials: Community Acquired Pneumonia (CAP), open to volunteers
Community Acquired Pneumonia (CAP)
Chest Radiography Versus Ultra-Low-Dose Chest Computed Tomography in Adults in the Emergency Department
Objective: To quantify and compare total staff person-time per imaging episode betweenconventional chest radiography (CXR) and ULDCT in adult emergency department patients in whom CAP is a differential diagnosis.
- Trial name
- TIME-CAP (NCT07870525)
- Testing
- ULDCT
- Where
- Denmark
- Volunteers
- 66 people
- Sponsor
- University of Southern Denmark
Community-acquired Pneumonia, CAP
Inhaled Lexofloxacin vs Usual Care for Treatment of Community-Acquired Pneumonia
This trial aims to determine whether treatment with inhaled levofloxacin (an antibiotic) is equal to systemic antibiotic treatment (usual care) for patients admitted to a hospital with community-acquired pneumonia in regards to…
- Conditions
- Community-acquired Pneumonia, CAP, Community Acquired Pneumonia, Pneumonia
- Trial name
- LANDCAP 2 (NCT07843017)
- Testing
- Inhaled levofloxacin, Standard-of-care / Usual care
- Volunteers
- 460 people
- Sponsor
- Copenhagen Respiratory Research
Community Acquired Pneumonia (CAP)
Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia
Aim: Demonstrate the equivalent efficacy and superior safety of Ceftriaxone 1 gram daily compared with Ceftriaxone 2 grams daily among hospitalized patients with community-acquired pneumonia who are not admitted to the intensive…
- Trial name
- DC-CAP (NCT07537413)
- Testing
- Ceftriaxone 1 gram daily, Ceftriaxone 2 grams daily
- Where
- 4 sites in United States
- Volunteers
- 900 people
- Sponsor
- University of Maryland, Baltimore
Community-acquired Pneumonia (CAP)
TCM Cohort for Elderly CAP
This study evaluates the real-world clinical efficacy of traditional Chinese medicine (TCM) in elderly Community-acquired pneumonia (CAP) patients and explores syndrome characteristics and their associations with biomarkers.
- Trial name
- NCT07797686
- Testing
- Traditional Chinese medicine (TCM), Non-traditional Chinese medicine (non-TCM)
- Where
- China
- Volunteers
- 2,234 people, healthy volunteers welcome
- Sponsor
- Henan University of Traditional Chinese Medicine
Community-Acquired Pneumonia (CAP)
Lefamulin Post-Market Surveillance Study
Community-acquired pneumonia (CAP) refers to infectious parenchymal lung inflammation acquired outside hospital settings. In China, its incidence is 7.13 per 1000 person-years, with over 10 million new cases annually.
- Trial name
- NCT07697885
- Testing
- This is a multicenter, single-arm, non-interventional study. No interventional measures will be adopted.
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Asthma (Diagnosis), Community-Acquired Pneumonia (CAP)
Multimodal Assisted Diagnosis for Pediatric Respiratory Diseases Using Questionnaires, Cough Sounds, and Breath Sounds
This study aims to establish a standardized, synchronized data collection system for pediatric symptom questionnaires, cough sounds, and breath sounds, and to construct a multimodal database of pediatric respiratory diseases…
- Trial name
- NCT07613242
- Testing
- Multimodal respiratory data collection
- Where
- China
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- Shanghai Children's Medical Center
Mild to Moderate, Community-Acquired Pneumonia (CAP)
Multicenter Phase II Trial of NRICM102 Combined With Standard Therapy in Pneumonia
The goal of this clinical trial is to learn if NRICM102 (a Traditional Chinese Medicine) works to treat community-acquired pneumonia (CAP) in adults when added to standard antibiotic therapy.
- Conditions
- Mild to Moderate, Community-Acquired Pneumonia (CAP), Antibiotic Therapy, Intravenous
- Trial name
- NCT07583992
- Testing
- NRICM102, Intravenous Antibiotic
- Where
- Taiwan
- Volunteers
- 150 people
- Sponsor
- National Research Institute of Chinese Medicine, Ministry of Health and Welfare
Inflammation, Community Acquired Pneumonia (CAP)
Targeting Vascular INflammation in Patients With Community-Acquired Pneumonia
The goal of this clinical trial is to learn if icosapent ethyl (Vascepa) works to lessen the amount of inflammation in adults diagnosed with Community-Acquired Pneumonia (CAP).
- Conditions
- Inflammation, Community Acquired Pneumonia (CAP), Inflammation Plaque, Atherosclerotic
- Trial name
- TIN-CAP (NCT06710080)
- Testing
- Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]
- Where
- Canada
- Volunteers
- 168 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Community-Acquired Pneumonia (CAP), Pneumonia
PromotIng Optimal Treatment for Community-acquired PNeumonia in EmErgency Rooms
In North America, up to 5% of preschoolers develop community-acquired pneumonia (CAP) every year. Pneumonia is the second-leading reason for paediatric hospitalization in both Canada and the US; approximately 20% of children…
- Trial name
- PIONEERS (NCT07099976)
- Testing
- The novel care pathway intervention, Usual Care Alone
- Where
- 6 sites in Canada
- Volunteers
- 698 people
- Sponsor
- Jeffrey Pernica
Community Acquired Pneumonia (CAP)
Comparing Hydrocortisone and Prednisolone for Community Acquired Pneumonia (CAP)
The goal of this cluster randomized controlled trial is to determine the optimal treatment for community aquired pneumonia (CAP).
- Trial name
- NCT06892197
- Testing
- Methylprednisolone (drug), hydrocortisone
- Where
- 14 sites in Denmark
- Volunteers
- 1,600 people
- Sponsor
- Copenhagen Respiratory Research
Community Acquired Pneumonia (CAP)
Effect of tNGS on CAP Patients With Initial Treatment Failure
This is a multicenter, randomized controlled trial designed to evaluate the impact of tNGS in patients with community-acquired pneumonia who experience initial treatment failure.
- Trial name
- NCT07472114
- Testing
- Targeted next-generation sequencing, Conventional microbiological testing, Follow-up at Day 30
- Where
- China
- Volunteers
- 524 people
- Sponsor
- Capital Medical University
Community Acquired Pneumonia (CAP), Community Acquired Pneumonia
Comparing Antibiotic Treatment Strategies for Children With Pneumonia in Outpatient Settings: (STAMPP)
The goal of this clinical trial is to determine if a "watch and wait" antibiotic strategy, called Safety Net Antibiotic Prescribing (SNAP), can safely reduce unnecessary antibiotic use while ensuring that children diagnosed with…
- Trial name
- STAMPP (NCT06986148)
- Testing
- Immediate Antibiotic Prescribing Group Instructions, Safety Net Antibiotic Prescribing (SNAP) Group Instructions
- Where
- 4 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Angina, Acute Bronchiolitis
Impact of a Multimodal Intervention on Antibiotic Prescribing for Respiratory Infections in Primary Care
Antimicrobial resistance (AMR), considered one of the greatest global threats by the WHO, justifies the development of initiatives to promote appropriate antibiotic use-especially in primary care, where most antibiotics in France…
- Conditions
- Angina, Acute Bronchiolitis, Acute Bronchitis, COPD Exacerbation (AECOPD)
- Trial name
- GRASP (NCT07359287)
- Testing
- Antibiotic prescribing according to guidelines
- Where
- France
- Volunteers
- 4,500 people
- Sponsor
- University Hospital, Caen
Community Acquired Pneumonia (CAP)
ItAlian ReGistry Of pNeumoniA in immUnocompromised paTients (ARGONAUT)
This multicentric, prospective study aims at: evaluating the prevalence, etiology, characteristics, and 1one-year outcomes of immunocompromised patients hospitalized for Community-Acquired Pneumonia (CAP); conducting biochemical…
- Trial name
- ARGONAUT (NCT06755814)
- Where
- Italy
- Volunteers
- 1,298 people
- Sponsor
- Societa Italiana di Pneumologia
Sepsis, Community Acquired Pneumonia (CAP)
OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis
OPT101-100-40 is a multicenter, randomized, placebo-controlled, multiple-ascending-dose, sequential-group, investigator- and participant-blinded, sponsor-unblinded, study of OPT101 vs placebo when administered for up to 4 days to…
- Trial name
- NCT06669403
- Testing
- OPT101
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Op-T LLC
Community Acquired Pneumonia (CAP), Hospital Acquired Pneumonia
Pneumonia Pathogens' Virulence Factors, Patient Inflammatory Markers, and Their Associations With Outcomes
The study aims to evaluate pneumonia symptoms using physical examinations, radiological and laboratory tests, and prognostic scales such as the Pneumonia Severity Index (PSI) and CURB65.
- Trial name
- Pneumonia-1 (NCT07011433)
- Testing
- Inflammatory Biomarker Evaluation
- Where
- Lithuania
- Volunteers
- 300 people
- Sponsor
- Ruta Nutautiene
Community Acquired Pneumonia (CAP)
Local Antibiotic Delivery for Community Acquired Pneumonia
A randomized, double-blinded clinical pilot study to assess whether addition of inhaled levofloxacin 240 mg twice daily for three days leads to improved or worsened physiological status in CAP patients with and without…
- Trial name
- LANDCAP-1 (NCT06859450)
- Testing
- Levofloxacin
- Volunteers
- 36 people
- Sponsor
- Copenhagen Respiratory Research
Community-Acquired Pneumonia (CAP)
Clinical Trial of Fei Re Qing Granules in the Treatment of Elderly Community-Acquired Pneumonia
This study aims to evaluate the clinical efficacy of traditional Chinese medicine formula granules (Fei Re Qing Granules) in the treatment of elderly community-acquired pneumonia, establish a treatment protocol, and obtain…
- Trial name
- NCT06747325
- Testing
- Fei Re Qing Granules, Routine standard treatments
- Volunteers
- 120 people
- Sponsor
- Henan University of Traditional Chinese Medicine
Community Acquired Pneumonia (CAP)
Clinical Characteristics and Outcome of Patients With Community Acquired Pneumonia
the goal of this observational study is to evaluate the clinical characteristic and outcomes of patients with community-acquired pneumonia admitted to Sohag University Hospital.
- Trial name
- NCT06716099
- Volunteers
- 100 people
- Sponsor
- Sohag University
Community-Acquired Pneumonia (CAP), Pneumonia
Clinical Impact of Rapid Molecular Testing for Pathogens in Patients With Severe Acute Respiratory Illness : A Pragmatic Trial
Community-acquired pneumonia (CAP) is among the most common reasons for emergency department (ED) visits. A clear understanding of the likely pathogens is essential for the rapid institution of adequate antimicrobial therapy.
- Trial name
- CIRT-RMT-SARI (NCT06605352)
- Testing
- The BIOFIRE®FILMARRAY® Pneumonia Panel
- Where
- Taiwan
- Volunteers
- 800 people
- Sponsor
- National Taiwan University Clinical Trial Center